![Qing Lei Zuo](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Qing Lei Zuo
No open positions remaining
Profile
Qing Lei Zuo worked as Head-Sales at Santen Pharmaceutical Co., Ltd. from 2015 to 2018.
Prior to that, he worked as Associate Product Manager at Eisai China, Inc. from 2010 to 2015 and as Preclinical Project Manager-R&D Department at Shanghai Hengrui Pharmaceutical Co., Ltd. in 2009-2010.
He also served as Vice President-Commercialization at Ocumension Therapeutics.
Mr. Zuo graduated from Shanghai Institute of Pharmaceutical Industry with a graduate degree in 2009 and from Yantai University with an undergraduate degree in 2006.
Former positions of Qing Lei Zuo
| Companies | Position | End |
|---|---|---|
| SANTEN PHARMACEUTICAL CO., LTD. | Sales & Marketing | 2018-07-31 |
Eisai China, Inc.
 Eisai China, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | 2015-02-28 |
Shanghai Hengrui Pharmaceutical Co., Ltd.
 Shanghai Hengrui Pharmaceutical Co., Ltd. Shanghai Hengrui Pharmaceutical Co., Ltd. specializes in the research, development, and promotion of innovative and high-quality drugs, with a focus on early-stage drug discovery. Shanghai Hengrui’s therapeutic areas include oncology, metabolism, cardiovascular diseases, autoimmune disorders, pain management, immune and respiratory diseases, and neuroscience. The company is based in Shanghai, China. The Chinese company operates advanced research laboratories and GMP-compliant production facilities, serving as the core innovation base for Hengrui Medicine. It is a major supplier of anti-tumor drugs, surgical medications, and imaging interventional products, and has developed proprietary technology platforms such as single B cell sequencing, bispecific and multispecific antibodies, antibody-drug conjugates, PROTAC technology, T cell engagers, and computer-aided drug design. The company has brought multiple innovative drugs to market, including early-developed class 1 innovative drugs for cancer, diabetes, and hematological diseases, and maintains a broad pipeline of drug candidates in preclinical and clinical phases, including targeted cancer therapies. | Corporate Officer/Principal | 2010-08-31 |
| OCUMENSION THERAPEUTICS | Corporate Officer/Principal | - |
Training of Qing Lei Zuo
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
29
1st degree connections
6
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Santen Pharmaceutical Co., Ltd.
 Santen Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and wholesales prescription drugs & medical devices to treat ophthalmology diseases | Health Technology |
Shanghai Institute of Pharmaceutical Industry
 Shanghai Institute of Pharmaceutical Industry Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yantai University
 Yantai University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Eisai China, Inc.
Eisai China, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Shanghai Hengrui Pharmaceutical Co., Ltd.
Shanghai Hengrui Pharmaceutical Co., Ltd. Shanghai Hengrui Pharmaceutical Co., Ltd. specializes in the research, development, and promotion of innovative and high-quality drugs, with a focus on early-stage drug discovery. Shanghai Hengrui’s therapeutic areas include oncology, metabolism, cardiovascular diseases, autoimmune disorders, pain management, immune and respiratory diseases, and neuroscience. The company is based in Shanghai, China. The Chinese company operates advanced research laboratories and GMP-compliant production facilities, serving as the core innovation base for Hengrui Medicine. It is a major supplier of anti-tumor drugs, surgical medications, and imaging interventional products, and has developed proprietary technology platforms such as single B cell sequencing, bispecific and multispecific antibodies, antibody-drug conjugates, PROTAC technology, T cell engagers, and computer-aided drug design. The company has brought multiple innovative drugs to market, including early-developed class 1 innovative drugs for cancer, diabetes, and hematological diseases, and maintains a broad pipeline of drug candidates in preclinical and clinical phases, including targeted cancer therapies. | |
Ocumension Therapeutics
 Ocumension Therapeutics Miscellaneous Commercial ServicesCommercial Services Operates as an ophthalmic pharmaceutical platform company that develops drugs | Commercial Services |
- Stock Market
- Insiders
- Qing Lei Zuo
